Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.1K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.1K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

2.2K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.2K
The Antiviral System of Bacteria and Archaea: CRISPR01:23

The Antiviral System of Bacteria and Archaea: CRISPR

821
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats is a adaptive immune system found in bacteria and archaea that protects against viral infections. This system enables prokaryotic cells to identify, remember, and neutralize foreign genetic elements, primarily bacteriophages, by storing fragments of the invader’s DNA as a genetic memory.The CRISPR immune response begins during an initial infection. Cas (CRISPR-associated) proteins play a central role in this...
821
RNA Interference01:23

RNA Interference

28.3K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.3K
Leaky Scanning02:28

Leaky Scanning

5.8K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.8K
Retroviruses02:33

Retroviruses

15.1K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
15.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A CXCL10-Expressing Influenza Vector Induces Robust Adaptive Immunity Despite Strong Attenuation.

Pharmaceutics·2026
Same author

Neomycin Exhibits Immunomodulatory and Antiviral Activity Against Influenza B Virus.

Viruses·2026
Same author

Chimeric Virus-like Particles Formed by the Coat Proteins of Single-Stranded RNA Phages Beihai32 and PQ465, Simultaneously Displaying the M2e Peptide and the Stalk HA Peptide from Influenza a Virus, Elicit Humoral and T-Cell Immune Responses in Mice.

Vaccines·2025
Same author

The Interplay Between Therapeutic Self-Amplifying RNA and the Innate Immune System: Balancing Efficiency and Reactogenicity.

International journal of molecular sciences·2025
Same author

Influence of Lipid Composition of Cationic Liposomes 2X3-DOPE on mRNA Delivery into Eukaryotic Cells.

Pharmaceutics·2023
Same author

Exosomes Released by Influenza-Virus-Infected Cells Carry Factors Capable of Suppressing Immune Defense Genes in Naïve Cells.

Viruses·2022

Related Experiment Video

Updated: Feb 28, 2026

Confocal Imaging of Double-Stranded RNA and Pattern Recognition Receptors in Negative-Sense RNA Virus Infection
06:44

Confocal Imaging of Double-Stranded RNA and Pattern Recognition Receptors in Negative-Sense RNA Virus Infection

Published on: January 26, 2019

8.4K

mRNA-Encoded Antibodies: An Emerging Paradigm in Antiviral Protection.

Sergey Klotchenko1, Marina Plotnikova1

  • 1Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation, 197022 Saint-Petersburg, Russia.

Biomolecules
|February 27, 2026
PubMed
Summary

Messenger RNA (mRNA) technology enables rapid, in vivo production of therapeutic antibodies, offering a flexible alternative to traditional methods for combating viral threats.

Keywords:
antibody engineeringantiviral prophylaxisbroadly neutralizing antibodies (bnAbs)in vivo expressioninfectious diseaseslipid nanoparticles (LNPs)mRNA therapeuticsmRNA-encoded antibodiespassive immunizationviral infections

More Related Videos

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.5K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

31.0K

Related Experiment Videos

Last Updated: Feb 28, 2026

Confocal Imaging of Double-Stranded RNA and Pattern Recognition Receptors in Negative-Sense RNA Virus Infection
06:44

Confocal Imaging of Double-Stranded RNA and Pattern Recognition Receptors in Negative-Sense RNA Virus Infection

Published on: January 26, 2019

8.4K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.5K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

31.0K

Area of Science:

  • Biotechnology
  • Immunology
  • Virology

Background:

  • Conventional recombinant antibody production is expensive and slow.
  • Messenger RNA (mRNA) technology allows for direct in vivo antibody expression.
  • Lipid nanoparticles encapsulate synthetic mRNA for therapeutic delivery.

Purpose of the Study:

  • Review recent advancements in mRNA-encoded antibodies for antiviral applications.
  • Compare mRNA-based antibody production with traditional protein-based therapies.
  • Discuss the clinical translation potential of this technology.

Main Methods:

  • Outline key technological principles of mRNA-encoded antibodies.
  • Review preclinical studies targeting various viral pathogens.
  • Analyze pharmacokinetic properties and delivery platforms.

Main Results:

  • mRNA-encoded antibodies demonstrate rapid expression and high serum concentrations in preclinical models.
  • Strong prophylactic and therapeutic efficacy observed against viral pathogens in animal models.
  • Phase I clinical trials initiated for specific viral targets, such as chikungunya virus.

Conclusions:

  • mRNA-encoded antibodies represent a flexible and rapidly deployable platform for passive immunization.
  • This technology shows significant promise for addressing emerging viral threats.
  • Further clinical development is warranted to fully realize the potential of mRNA-based antibody therapies.